Dimethyltryptamine (copyright) inhabits a complex and sometimes contradictory legal status across European nations. While some countries have outright prohibited the substance, others maintain a more ambiguous stance, leaving its legality open to scrutiny. This regulatory ambiguity stems from a variety of factors, including differing societal attit